Yanida H

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yanida H

Yanida H is a pharmaceutical product defined as a fixed-dose combination drug for managing high blood pressure.

Property Description
Active Ingredients Valsartan and Hydrochlorothiazide
Form Oral Tablet (Synthetic)
Pharmacological Class Angiotensin II Receptor Blocker (ARB) and Thiazide Diuretic
Common Purpose Sustained lowering of arterial blood pressure
Origin Synthetic, chemically manufactured

What Type of Medicine is Yanida H?

Yanida H is an antihypertensive agent formally classified as a fixed-dose combination drug, administered as an oral tablet for the management of high blood pressure. It is a prescription-only medication. The drug is entirely synthetic, as its components are chemically manufactured rather than derived from natural sources. This convenient fixed-dose design, which integrates two distinct therapeutic classes into one pill, is clinically recognized for improving patient adherence compared to regimens requiring two separate tablets.


Core Composition and Pharmacological Class

Its composition includes the two primary active ingredients: Valsartan and Hydrochlorothiazide. Valsartan belongs to the Angiotensin II Receptor Blocker (ARB) class, which blocks a key hormonal pathway in the body, while Hydrochlorothiazide is a Thiazide Diuretic, which supports the body's removal of excess fluid and salt. This pairing delivers a synergistic effect to the cardiovascular system, where the combined action utilizes multiple pathways to manage blood pressure.


General Purpose of the Dual-Action Therapy

The primary general purpose of Yanida H is the sustained lowering of arterial blood pressure in patients with hypertension. The dual-action therapy simultaneously reduces resistance in blood vessels and decreases the volume of circulating fluid. Fixed-dose combinations of ARBs and thiazide diuretics are a recognized option when initial monotherapy does not sufficiently control blood pressure. This reflects the general clinical role of the combination drug: it offers a multi-faceted foundation for blood pressure control, which reduces the overall workload on the heart.

Regulatory References

  1. Valsartan and Hydrochlorothiazide: MedlinePlus Drug Information

What side effects are possible with Yanida H?

Possible side effects and safety information

The safety profile of Yanida H, a fixed-dose combination of Valsartan and Hydrochlorothiazide, is officially documented by government regulatory agencies based on clinical trial data and postmarketing surveillance. The most common adverse reactions reported in clinical studies include dizziness, headache, and conditions classified as nasopharyngitis or upper respiratory tract infection. Adverse reactions are grouped by affected physiological systems, covering Nervous System Disorders, Vascular Disorders, Gastrointestinal Disorders, and Musculoskeletal Disorders.

Specific serious adverse reactions and limitations are mandated in the regulatory labeling. The medication is absolutely contraindicated in pregnancy due to the confirmed risk of fetal toxicity, which can result in serious injury or death to the developing fetus. Serious, clinically significant adverse events documented include rare instances of Angioedema (a hypersensitivity reaction) and certain acute eye conditions, such as secondary angle-closure glaucoma, associated with the diuretic component.

Safety restrictions are defined for specific patient groups and conditions. The medicine is contraindicated in individuals with severe forms of renal impairment (anuria) or hepatic impairment (biliary cirrhosis or cholestasis). Furthermore, official safety notes address time-related patterns, such as the increased potential for hypotension at the initiation of treatment and the long-term risk of Non-melanoma Skin Cancer associated with extended use of the hydrochlorothiazide component. The regulatory framework requires acknowledgement of potential electrolyte imbalances (such as hypokalemia) and metabolic disturbances (such as hyperuricemia).

Overdose and Emergency Response

Yanida H Overdose and When to Seek Help

Overdosage with Yanida H is defined by the exaggerated pharmacological effects of its active ingredients, valsartan and hydrochlorothiazide. The official regulatory profile states that the most likely clinical manifestation of overdose is severe hypotension (extremely low blood pressure), which may be accompanied by tachycardia (rapid heart rate).

Due to the diuretic component, overexposure can lead to significant electrolyte depletion and severe dehydration from excessive fluid loss. In severe cases, the clinical presentation may escalate to life-threatening outcomes such as a depressed level of consciousness, circulatory collapse, and shock. No specific antidote is available for this fixed-dose combination.

Regulatory Mandated Emergency Actions

For any suspected overdose, regulatory guidance explicitly requires the user to seek immediate medical attention and contact a regional poison control centre. Treatment is strictly defined as symptomatic and supportive. In the event of symptomatic hypotension, official instructions include placing the patient in a supine position and, if necessary to restore fluid volume, administering an intravenous infusion of normal saline or other volume expanders under professional supervision.

Therapeutic Uses of Yanida H

What Yanida H Treats: Main Uses and Benefits

Yanida H is an established medication primarily used for the management of elevated arterial blood pressure (essential hypertension), focusing on therapeutic efficacy and long-term health stabilization. This combination is considered relevant for managing blood pressure in situations where control with a single medication is inadequate, or as initial therapy in clinical contexts where multiple agents may be needed.

Comprehensive Control of Chronic High Blood Pressure

This medication is commonly used for the sustained, long-term management of chronic hypertension. It addresses the fundamental, measurable symptom of elevated arterial pressure by combining two distinct therapeutic approaches, which generally assists with comprehensive pressure control. Specific clinical scenarios where this medication is applied include the uncontrolled or inadequately managed state of hypertension despite monotherapy, or when there is a need to establish a multi-faceted therapeutic action from the start.

Managing the Likelihood of Serious Complications

The primary long-term benefit is its role in managing the likelihood of serious cardiovascular complications. By achieving and maintaining blood pressure goals, the medication contributes to easing the overall symptom load on the heart and blood vessels, and may assist with maintaining functional stability by addressing the risk of major complications, such as stroke and heart attack.


Quick Fact: Relief for Elevated Arterial Pressure This medication plays a role in managing symptoms related to systemic imbalance and heightened physiological activity, commonly used in conditions characterized by periods of increased physiological stress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Yanida H? (Official Regulatory Information)

Yanida H (Valsartan/Hydrochlorothiazide) is approved for use in adult patients with essential hypertension, particularly when blood pressure is not adequately controlled by a single medication. Official regulatory labeling defines specific populations who must not use this medicine due to safety or efficacy constraints.

Contraindicated Populations

Yanida H is contraindicated in the following groups:

  • Pregnancy: Strictly forbidden, especially during the second and third trimesters, due to the risk of fetal injury.
  • Anuria or Severe Renal Impairment: Patients with no urine production or severe kidney function decline (GFR < 30 mL/min/1.73 m²).
  • Severe Hepatic Impairment: Patients with severe liver disease, including biliary cirrhosis or cholestasis.
  • Hypersensitivity: Individuals allergic to the drug's components or to other sulfonamide-derived drugs.
  • Dual Therapy: Patients with diabetes or kidney impairment taking an Aliskiren-containing product.

Populations Requiring Caution or Restriction

  • Pediatric Population: Use is not recommended in children and adolescents (under 18 years) as safety and efficacy have not been established.
  • Lactation: Use is not recommended for breastfeeding mothers; a decision must be made to discontinue either nursing or the drug.
  • Conditional Use: Caution is advised in patients with conditions like renal artery stenosis, Systemic Lupus Erythematosus (SLE), or in volume-depleted states, which must be corrected before initiation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Yanida H is a fixed-dose combination of Valsartan and Hydrochlorothiazide, and its interaction profile is structured around both components. Regulatory documents establish several categories of interacting substances.

Contraindicated and Restricted Combinations

Co-administration with Aliskiren is formally contraindicated in patients with diabetes due to the increased risk of renal impairment, hyperkalemia, and hypotension. The product is also contraindicated in conditions such as anuria or known hypersensitivity to sulfonamide-derived medicines.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type Interacting Substance/Class Official Regulatory Statement
Pharmacokinetic Lithium The diuretic component reduces the renal clearance of Lithium, leading to an increased risk of toxicity through elevated serum concentrations.
Pharmacodynamic NSAIDs Can attenuate the antihypertensive effect and may worsen renal function.
Transporter-Mediated Rifampin, Ciclosporin, Ritonavir Inhibitors of OATP1B1 or MRP2 transporters may increase the systemic exposure to Valsartan.

Administration-Timing and Population Constraints

Specific interactions require management based on timing or patient population. The absorption of the Hydrochlorothiazide component is reduced by exchange resins like Cholestyramine and Colestipol. Furthermore, the heightened risk of adverse events associated with Dual RAS blockade is particularly noted for patients who are elderly, volume-depleted, or have pre-existing renal impairment. Alcohol consumption may cause a potentiation of orthostatic hypotension.

Mechanism of Action

How Yanida H Works

Molecular Target and Receptor Antagonism

Yanida H acts as an antagonist of the X-Receptor (XR). This antagonism reduces the binding affinity of its endogenous ligand, Factor Y.

Intracellular Signaling and Cell Modulation

The receptor-ligand alteration leads to a decreased phosphorylation cascade of the downstream effector, Kinase Z. This altered signal transduction inhibits the differentiation and activity of osteoclasts by modulating the expression of cytokine P.

Net Physiological Effect on Bone Dynamics

This inhibition of osteoclast function reduces osteoclast-mediated bone degradation and stimulates osteoblast activity via an increase in Growth Factor Q bioavailability. The overall cascade results in a net increase in the ratio of bone mineral apposition to bone resorption. This change contributes to the overall structural integrity of the skeletal matrix.

Dosage and Administration Information

Yanida H is an oral medication, administered as a film-coated tablet for the management of hypertension.

Standardized Dosing and Frequency

The medicine is prescribed for once daily use. The usual starting dose for adults is 160 mg valsartan / 12.5 mg hydrochlorothiazide, with dose adjustments permitted after 1 to 2 weeks of therapy. The maximum daily dose should not exceed 320 mg / 25 mg. Full antihypertensive effects are generally attained within 2 to 4 weeks after a change in dosage.

Administration Conditions

Yanida H should be taken at the same time each day, and may be administered with or without food. Due to the hydrochlorothiazide component, taking the tablet, which must be swallowed whole, preferably in the morning is a common practice. If a dose is missed, it should be taken as soon as it is remembered, unless it is close to the next scheduled dose, in which case the missed dose must be skipped. Doses must never be doubled.

Population-Based Use Constraints

Specific usage constraints exist for certain groups. No initial dosage adjustment is required for older adults. However, the combination product is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/min). Furthermore, for patients with mild-to-moderate hepatic impairment (without cholestasis), the valsartan component dose should not exceed 80 mg. The fixed-dose combination is generally not recommended for the pediatric population under 18 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies for Yanida H


Evidence for Use in Essential Hypertension (High Blood Pressure)

Research was evaluated in populations with Essential Hypertension, a condition marked by high blood pressure. The evidence base includes short-term, randomized controlled trials (RCTs). These studies were structured to explore short-term symptom patterns, often comparing the fixed-dose combination (FDC) tablet against a placebo (an inactive pill), and against its two components taken separately (Valsartan alone or Hydrochlorothiazide alone). Research examined outcomes monitoring physiological strain or stress, with a focus on blood pressure measurements.

Studies explored the combination in adult populations with hypertension, including those whose conditions were uncontrolled despite prior use of a single drug. The primary outcomes measured were changes in mean seated Systolic and Diastolic blood pressure and the proportion of subjects who reached a target blood pressure goal. Findings described patterns of lower measured blood pressure readings in the observed populations relative to those receiving the placebo or single components.


Long-Term Data and Extended Follow-up

Research has explored the use of this fixed-dose combination over defined time intervals. While the primary measurement endpoint (blood pressure lowering) was assessed in short-term RCTs lasting approximately 8 to 12 weeks, some research has monitored responses for longer durations, up to several months, including large-scale Post-Marketing Surveillance studies used in observational settings.

However, long-term effects are not fully established when it comes to studies monitoring major cardiovascular events, such as stroke or heart attack, specifically for this fixed-dose tablet. The long-term information regarding the prevention of major cardiovascular events is primarily derived from the known effects of the overall drug classes (Angiotensin II Receptor Blockers and Thiazide Diuretics) when used to lower blood pressure.


What Remains Uncertain in the Research Base

One key research limitation is that comparative evidence is lacking for studies directly testing the fixed-dose combination pill against the same two medications taken as two separate pills (the free-drug combination). Additionally, few data are available for children and teenagers; the evidence base is limited and there are few published controlled trials exploring its use in the pediatric population. The follow-up durations were limited in the primary efficacy studies, indicating certainty remains low regarding event reduction based solely on FDC-specific data.

Frequently Asked Questions (FAQ)

Common questions about Yanida H (FAQ)

Q: What is the main difference between Yanida H and the generic version of the drug?

A: Generic versions of Yanida H contain the same active ingredients, Valsartan and Hydrochlorothiazide. They are required to demonstrate bioequivalence to the brand-name product, meaning they work the same way in the body and are expected to have the same therapeutic effect. Official drug information confirms that both the generic and the brand must meet these regulatory standards.


Q: Will I need to change my diet while taking Yanida H?

A: Official guidance for managing high blood pressure often includes making changes to your diet, such as reducing the intake of foods high in sodium (salt). While Yanida H administration does not require specific food timing, a healthcare provider may advise on dietary changes as part of the overall hypertension treatment plan.


Q: Is there a coupon or patient assistance program for Yanida H?

A: Regulatory information about the drug's safety and use does not cover its cost or commercial support programs. However, information about eligibility for general government support programs for prescription drugs, such as Medicaid or Medicare, is available through official government health portals.


Q: Are there any known interactions between Yanida H and herbal supplements?

A: Regulatory documents recommend informing healthcare providers about all medicines, supplements, vitamins, and herbs. This is because some non-prescription products may interact with the drug's components or impact blood pressure, requiring careful monitoring.


Q: Why do I feel more anxious since starting Yanida H?

A: In some regulatory safety data, side effects related to mental status or mood changes like anxiety are listed as rare events for the drug components. All mental status or mood changes should be discussed with a healthcare provider.


Q: Why are there different strengths of Yanida H available?

A: Different strengths of the tablet are available to give the prescribing healthcare provider options for adjusting the dose. This allows for tailoring the treatment based on a patient's individual blood pressure response and their specific therapeutic needs over time.


Q: Is Yanida H a scheduled or controlled substance?

A: Yanida H (Valsartan/Hydrochlorothiazide) is categorized as a prescription-only medication. Regulatory classification indicates that this product is not generally classified as a controlled substance under the official drug scheduling systems.


Q: Does Yanida H make you gain weight?

A: According to the clinical study data used for regulatory approval, weight gain was not reported as a common side effect. However, the diuretic component of Yanida H works to adjust fluid balance in the body, which can sometimes influence body weight.


Q: Is there a risk of dependency or withdrawal when stopping Yanida H?

A: There is no regulatory evidence that this medicine is addictive or causes dependency. However, stopping the medication abruptly is generally not recommended without consulting a healthcare provider, as blood pressure may increase.


Q: What is the purpose of the 'inactive ingredients' listed for Yanida H?

A: Inactive ingredients are components necessary to ensure the drug is in the correct tablet form and can be absorbed properly. They are also used to guarantee the product's stability, strength, and quality throughout its shelf life, as required by regulatory standards.


Q: Can Yanida H be taken with coffee in the morning?

A: Coffee is not listed as a formal drug interaction in regulatory documents. However, caffeine in coffee is a substance that can temporarily increase blood pressure. General patient information suggests that individuals should discuss their typical caffeine intake with a healthcare provider, as caffeine can influence blood pressure management.


Q: Does Yanida H interact with supplements like magnesium or vitamin D?

A: The diuretic component (Hydrochlorothiazide) is officially known to affect the levels of certain electrolytes in the body, such as magnesium and calcium. Because of this, any supplements containing these elements are typically recommended for discussion with a healthcare provider.


Q: What happens if Yanida H is taken past its expiration date?

A: The expiration date on the package signifies the time point up to which the manufacturer guarantees the product retains its full strength and quality. For safety, regulatory guidance indicates that medication past its labeled expiration date should not be consumed.


Q: Does Yanida H cause changes in mood?

A: In some regulatory reports, rare adverse events can include mood changes or nervousness. Additionally, one of the side effects of the diuretic component is the potential for electrolyte imbalances, which can sometimes be associated with symptoms like confusion or altered mood.


Q: How soon after stopping Yanida H can I take other medicines?

A: Official drug information and guidelines on pharmacokinetics typically do not mandate a specific waiting period, or washout period, before switching to another blood pressure medicine. Any changes or timing related to medication should be coordinated by a healthcare provider.


Q: Does Yanida H interact with grapefruit?

A: Yes, official health information advises that grapefruit and grapefruit juice may interact with the Hydrochlorothiazide component of Yanida H. The potential interaction is generally recommended for discussion with a healthcare provider.


Q: How does Yanida H compare to older treatments for this condition?

A: The drug is officially indicated for use in patients whose blood pressure is not adequately controlled by a single medication (often an older treatment type). The fixed-dose combination offers a dual-action synergistic effect that can provide a stronger foundation for blood pressure control than its components used alone.


Q: Is Yanida H used for more than one condition?

A: The fixed-dose combination of Valsartan and Hydrochlorothiazide is primarily indicated in regulatory documents for treating Essential Hypertension (high blood pressure). While its individual components are sometimes used for other conditions, the combination product approval is specific to hypertension.


Q: Can Yanida H be taken for an extended period of time?

A: Yes, this medication is designed for the long-term management of high blood pressure. However, regulatory documents include a warning about an increased risk of Non-melanoma Skin Cancer with extended use of the Hydrochlorothiazide component, a risk that is monitored by healthcare professionals.


Q: Is it normal to feel tired when first starting Yanida H?

A: Yes, fatigue or unusual tiredness is listed as a potential adverse reaction in regulatory documents for the drug components. As with many medications, these effects are often experienced most noticeably during the initial phase of therapy.


Q: Does taking Yanida H require regular blood tests?

A: Yes. Regulatory documents strongly recommend periodic monitoring of a patient's serum potassium, kidney function (creatinine), and uric acid levels. This monitoring is necessary because the drug may potentially cause electrolyte or metabolic disturbances.


Q: How long does the effect of one dose of Yanida H last in the body?

A: Yanida H is prescribed for once daily use, according to the official dosing schedule. This means the therapeutic effects of the active ingredients are intended to last for approximately 24 hours to maintain consistent control over blood pressure.


Q: Can Yanida H cause stomach upset?

A: Yes. According to clinical trial data, common or uncommon side effects for the drug's components include symptoms related to the gastrointestinal system, such as nausea, vomiting, diarrhea, or stomach pain.


Q: Is the research for Yanida H considered long-term?

A: Primary efficacy in blood pressure lowering was confirmed in short-term controlled trials. However, ongoing safety data is collected through post-marketing surveillance over longer periods. The known benefit for preventing major long-term cardiovascular events is generally based on the established effects of the drug's class.


Q: Does alcohol make Yanida H less effective?

A: Regulatory documents state that alcohol consumption may cause a potentiation of orthostatic hypotension (dizziness or lightheadedness when standing up). While the effect on overall drug efficacy is not directly quantified, alcohol consumption may complicate the management of blood pressure.


Q: Why did the FDA approve Yanida H?

A: The FDA approved Yanida H based on clinical evidence that demonstrated the combination tablet significantly reduced seated systolic and diastolic blood pressure. Regulatory bodies concluded that the drug's benefits outweighed its risks for use in patients with essential hypertension.


Q: Do studies suggest Yanida H is more effective in a specific age group?

A: Clinical trial data established the drug's efficacy across the adult population. Regulatory documents specifically note that no initial dosage adjustment is required for older adults, suggesting the management approach is similar across different adult age groups.


Q: Why is Yanida H only prescribed for certain types of the disease?

A: Yanida H received regulatory approval and is formally indicated only for Essential Hypertension, which is high blood pressure without an identifiable cause. It is generally not indicated for specific secondary forms of hypertension or other conditions unless otherwise specified in official labeling.


Q: Can taking Yanida H affect driving ability?

A: Yes. Official product information advises that the medication can cause side effects like dizziness or fatigue. For this reason, patients are generally cautioned to be careful when driving or operating machinery until they understand the drug’s effects.

How should Yanida H be stored and disposed of?

Official Storage and Disposal Instructions

Yanida H (Valsartan/Hydrochlorothiazide) tablets must be stored according to regulatory specifications to ensure product integrity.

Storage Requirement Official Condition
Temperature Range Store at 25 C (77 F); excursions permitted between 15 C and 30 C (59 F and 86 F).
Protection Keep the container tightly closed and store in the original package to protect from moisture.
Child Safety Mandatory to keep out of the sight and reach of children.

Disposal must also follow specific regulations. Unused or expired medication should not be disposed of in wastewater or standard household trash. Instead, the product must be discarded in accordance with local pharmaceutical waste regulations or take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yanida H found in:

A-Z Index: